The study included approximately 200 female volunteers between the ages of 20 and 79. The clinical trials aimed at assessing phalangeal bone mineral density using two x-ray methods being direct exposure and screened exposure, acquired with common intensifying screens. The results showed a very high correlation between the two methods.
"The latest beta testing feedback and current clinical trial results assure that the Automated OsteoGram is a reliable tool for assessing bone mineral density. We are very pleased with the conclusion of these studies and look forward toward a successful launch of our product in the very near future", stated Robert B. Goldberg, Chairman and CEO of CompuMed.
CompuMed, headquartered in Los Angeles, California, develops solutions to important medical problems through the use of computer technology. In addition to the Automated OsteoGram, the company has developed and is marketing computer-aided telemedicine services for cardiology and currently provides on-line computer interpretation of electrocardiograms (ECG's) to physicians, government and corporate health care providers.